Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma

Journal of Immunotherapy

Volumn 36, Issue 3, 2013, Pages 215-222

  Wilgenhof, Sofie ^a   Four, Stephanie Du ^a   Vandenbroucke, Frederik ^a   Everaert, Hendrik ^b   Salmon, Isabelle ^c   Liénard, Danielle ^a   Marmol, Véronique Del ^a   Neyns, Bart ^a  

^a Laarbeeklaan 101 ^*  (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c ERASME HOSPITAL   (Belgium)

Author keywords

cytotoxic T lymphocyte associated antigen 4; expanded access program; immunotherapy; ipilimumab; melanoma

Indexed keywords

C REACTIVE PROTEIN; IPILIMUMAB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COLITIS; DIARRHEA; FEMALE; GUILLAIN BARRE SYNDROME; HEPATITIS; HUMAN; HYPOTHYROIDISM; LYMPHOCYTE COUNT; MALE; MELANOMA; OVERALL SURVIVAL; PANCREATITIS; PRIORITY JOURNAL; PRURITUS; RADIATION NECROSIS; RASH; SARCOIDOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS; VITILIGO;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; CTLA-4 ANTIGEN; FEMALE; HUMANS; LYMPHOCYTE COUNT; MALE; MELANOMA; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84875343764     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31828eed39     Document Type: Article

References (26)

1. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet. 2005;365:687-701.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-2526.
3. Chapman PB, Hauschild A, Robert C, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma [ASCO Meeting Abstracts]. J Clin Oncol. 2012;30(suppl):8502.
4. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7:95-106.
5. Engelhardt JJ, Sullivan TJ, Allison JP. CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol. 2006;177:1052-1061.
6. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26: 5275-5283.
7. Hodi F, O'Day S, McDermott D, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
8. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010;21:1712-1717.
9. Weber J, Thompson JA, Hamid O, et al. A randomized, doubleblind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591-5598.
10. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, doseranging study. Lancet Oncol. 2010;11:155-164.
11. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15: 7412-7420.
12. Weber JS, Kahler KC, Hauschild A. Management of immunerelated adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-2697.
13. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13(pt 1):6681-6688.
14. Hamid O, Schmidt H, Nissan A, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204.
15. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 2010;37:473-484.
16. Berman DM, Wolchok J, Weber J, et al. Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab [ASCO Meeting Abstracts]. J Clin Oncol. 2009;27(15S):3020.
17. Carthon BC, Wolchok JD, Yuan J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010;16: 2861-2871.
18. Sarnaik AA, Yu B, Yu D, et al. Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res. 2011;17:896-906.
19. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol. 2011;22:991-993.
20. Du Four S, Wilgenhof S, Duerinck J, et al. Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. Eur J Cancer. 2012;48: 3045-3051.
21. Wolchok J, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, doseranging study. Lancet Oncol. 2010;11:155-164.
22. Hodi FS, O'Day S, McDermott DF, et al. Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma [ASCO Meeting Abstracts]. J Clin Oncol. 2010; 28(suppl):8509.
23. Marshall MA, Ribas A, Huang B. Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma [ASCO Meeting Abstracts]. J Clin Oncol. 2010; 28(suppl):2609.
24. Tartour E, Blay JY, Dorval T, et al. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol. 1996;14:1697-1703.
25. Negrier S, Perol D, Menetrier-Caux C, et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin- 6-from the Groupe Francais d'Immunotherapie. J Clin Oncol. 2004;22:2371-2378.
26. Ku GY, Yuan J, Page DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010;116:1767-1775.